Vunakizumab ELISA Kit

SKU: DS856078

Size:96T

Applications:ELISA

Accession:Q16552

Stability and Storage:The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method:Colorimetric

Sample type:Plasma, Serum

Assay type:Quantitative

Sensitivity:0.156 μg/ml

Range:0.31-5 μg/mL

Recovery:80-120%

Properties:

Experimental Procedure:

Background:Vunakizumab is a recombinant humanized IgGκ monoclonal antibody binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). It was discovered and developed by Jiangsu Hengrui Medicine (China) with the developmental name SHR-1314, for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. Atridia Pty. Ltd., which is now a part of Jiangsu Hengrui Medicine, start a phase-I clinical trial in psoriasis (in volunteers) in Australia in August 2016. Atridia completed the phase-I trial in July 2017. A phase-I/II study, which is started from December 2017, is ongoing to assess the safety, tolerability, and pharmacokinetics of SHR-1314 with expanded dose finding in subjects with moderate-to-severe plaque psoriasis.

Alternative Names:SHR-1314, 1792181-33-9

Shipping:2-8 ℃

Note:For Research Use Only.